| Primary |
| Acute Lymphocytic Leukaemia |
55.6% |
| Non-hodgkin's Lymphoma |
12.2% |
| B Precursor Type Acute Leukaemia |
8.9% |
| Product Used For Unknown Indication |
7.8% |
| Lymphoma |
2.2% |
| Natural Killer-cell Lymphoblastic Lymphoma |
2.2% |
| Acute Leukaemia |
1.1% |
| Angiocentric Lymphoma |
1.1% |
| Angioimmunoblastic T-cell Lymphoma |
1.1% |
| Chloroma |
1.1% |
| Lymphocytic Leukaemia |
1.1% |
| Precursor B-lymphoblastic Lymphoma |
1.1% |
| Precursor T-lymphoblastic Lymphoma/leukaemia |
1.1% |
| Prophylaxis |
1.1% |
| T-cell Lymphoma |
1.1% |
| T-cell Type Acute Leukaemia |
1.1% |
|
| Pancreatitis Acute |
17.0% |
| Hyperglycaemia |
8.5% |
| Hyperlipidaemia |
8.5% |
| Pancreatitis |
8.5% |
| Pancreatitis Necrotising |
6.4% |
| Hypersensitivity |
4.3% |
| Hypertriglyceridaemia |
4.3% |
| Intracranial Venous Sinus Thrombosis |
4.3% |
| Leukopenia |
4.3% |
| Liver Disorder |
4.3% |
| Protein Total Decreased |
4.3% |
| Thrombosis |
4.3% |
| Tumour Lysis Syndrome |
4.3% |
| Vomiting |
4.3% |
| Blood Triglycerides Increased |
2.1% |
| Cerebral Thrombosis |
2.1% |
| Cerebral Venous Thrombosis |
2.1% |
| Congenital Aplastic Anaemia |
2.1% |
| Convulsion |
2.1% |
| Embolism Venous |
2.1% |
|
| Secondary |
| Acute Lymphocytic Leukaemia |
69.1% |
| Chromosome Analysis Abnormal |
7.2% |
| B Precursor Type Acute Leukaemia |
4.5% |
| Product Used For Unknown Indication |
2.7% |
| Prophylaxis |
2.4% |
| Precursor T-lymphoblastic Lymphoma/leukaemia |
1.5% |
| T-cell Type Acute Leukaemia |
1.4% |
| Antifungal Prophylaxis |
1.2% |
| Haematological Malignancy |
1.2% |
| Lymphocytic Leukaemia |
1.2% |
| Drug Use For Unknown Indication |
1.1% |
| Acute Myeloid Leukaemia |
0.9% |
| Precursor B-lymphoblastic Lymphoma |
0.8% |
| Natural Killer-cell Lymphoblastic Lymphoma |
0.8% |
| Non-hodgkin's Lymphoma |
0.8% |
| Chemotherapy |
0.7% |
| Prophylaxis Against Graft Versus Host Disease |
0.7% |
| B-cell Type Acute Leukaemia |
0.7% |
| Lymphoma |
0.6% |
| T-cell Lymphoma |
0.5% |
|
| Off Label Use |
13.6% |
| Renal Vein Thrombosis |
10.8% |
| Thrombosis |
9.2% |
| Sepsis |
6.0% |
| Zygomycosis |
6.0% |
| Posterior Reversible Encephalopathy Syndrome |
5.2% |
| Glioma |
4.8% |
| Reversible Posterior Leukoencephalopathy Syndrome |
4.8% |
| Venous Thrombosis |
4.8% |
| Staphylococcal Infection |
4.4% |
| Vomiting |
4.4% |
| Subclavian Vein Thrombosis |
4.0% |
| Neutropenia |
3.2% |
| Hepatotoxicity |
2.8% |
| Hypotension |
2.8% |
| Pancreatitis |
2.8% |
| Thrombocytopenia |
2.8% |
| Treatment Related Secondary Malignancy |
2.8% |
| Anaphylactic Reaction |
2.4% |
| Cardiac Failure Congestive |
2.4% |
|
| Concomitant |
| Acute Lymphocytic Leukaemia |
36.4% |
| Lymphoma |
18.6% |
| Product Used For Unknown Indication |
9.7% |
| Precursor T-lymphoblastic Lymphoma/leukaemia |
4.5% |
| B Precursor Type Acute Leukaemia |
4.1% |
| Antifungal Prophylaxis |
3.4% |
| Chemotherapy |
2.9% |
| Diffuse Large B-cell Lymphoma Stage Iii |
2.6% |
| Gastritis Prophylaxis |
2.6% |
| Acute Leukaemia |
2.5% |
| Bone Marrow Conditioning Regimen |
2.2% |
| Prophylaxis Against Graft Versus Host Disease |
2.2% |
| Leukaemia |
1.8% |
| Angioimmunoblastic T-cell Lymphoma |
1.5% |
| B-cell Lymphoma Stage Iii |
1.3% |
| Drug Use For Unknown Indication |
0.9% |
| Prophylaxis |
0.9% |
| Neoplasm Malignant |
0.7% |
| Chronic Graft Versus Host Disease |
0.6% |
| Epilepsy |
0.6% |
|
| Retinal Vein Thrombosis |
24.7% |
| Toxic Skin Eruption |
9.6% |
| Toxicity To Various Agents |
6.8% |
| Acute Respiratory Distress Syndrome |
5.5% |
| Septic Shock |
5.5% |
| Hemiparesis |
4.1% |
| Neurotoxicity |
4.1% |
| Stomatitis |
4.1% |
| Thrombosis |
4.1% |
| Viral Infection |
4.1% |
| Cardio-respiratory Arrest |
2.7% |
| Central Nervous System Lesion |
2.7% |
| Cholestasis |
2.7% |
| Conjunctivitis |
2.7% |
| Epstein-barr Virus Associated Lymphoproliferative Disorder |
2.7% |
| Hyperglycaemia |
2.7% |
| Monoparesis |
2.7% |
| Pleural Fibrosis |
2.7% |
| Pseudobulbar Palsy |
2.7% |
| Renal Tubular Necrosis |
2.7% |
|
| Interacting |
| Acute Lymphocytic Leukaemia |
83.3% |
| Neoplasm |
16.7% |
|
| Hypofibrinogenaemia |
50.0% |
| Somnolence |
50.0% |
|
